Illumina has rallied 20% in a month. The loudest response has come not from bulls adding to positions, but from a board-level insider selling tens of millions of dollars into the strength.
Keith Meister — who controls Corvex Management and holds a board seat — unloaded more than 235,000 shares between May 29 and June 1, with the bulk of the selling concentrated on Monday at prices between $162 and $166. The combined value across those two days ran north of $40 million. Meister remains a significant holder, with just over 3.5 million shares reported as of late May, but the pace and size of the selling is hard to ignore given he was the most active seller in the period. A smaller clip came from Chief Accounting Officer Scott Ericksen, who sold 500 shares at $160 on May 29 — a token amount by comparison, but part of a pattern of insider disposals at current levels. The net 90-day insider flow for the stock, at roughly 1 million shares and $158 million on the buy side in aggregate, is distorted by how those figures are calculated; the near-term direction of traffic is clearly outbound.
The short interest story adds a layer of tension. Bears have quietly rebuilt positions over the past week — short interest climbed 11% in seven days to just above 5% of the free float, clawing back ground lost in mid-May when it briefly dipped toward 4.4%. That one-week jump is the sharpest in the recent history window and leaves SI at its highest level of the tracked period. Days to cover is a meaningful 4 days per the latest FINRA print, not a squeeze setup but enough to create friction if sentiment flips. The lending market, though, tells a different story: availability is at 1,472% — an enormous cushion — meaning new shorts face no difficulty borrowing. Cost to borrow has drifted lower to 0.40%, close to its floor for the period. There is no squeeze pressure here; bears can add freely and are doing so.
Options positioning, by contrast, looks distinctly sanguine. The put/call ratio has collapsed from above 0.58 in early May to just 0.41 now — well below its 20-day average of 0.47 and running near the more bullish end of its 52-week range. Call demand has surged relative to puts as the stock ripped higher through May. That divergence — options traders leaning optimistic while short sellers rebuild and a board-linked seller takes chips off the table — is the core tension of this week's setup.
The Street is broadly positive but with meaningful caveats. Guggenheim lifted its target to $180 on June 1, the freshest action, maintaining a Buy. RBC Capital reinstated coverage at Outperform with a $170 target in mid-May. Both land above the current price. But JP Morgan held Neutral and raised only to $125, and Barclays kept Underweight even while nudging its target to $122 — both well below $162. Citigroup still carries a Sell with a $95 target. The mean analyst target of $144 is actually below the current share price, a configuration that tends to slow incremental institutional buying. The bull case rests on Illumina's dominant next-generation sequencing franchise, improving gross margins, and clinical market expansion. Bears point to weakening research end-market demand, flat pharma spending, ongoing China headwinds, and competition from Roche. Both camps find data to support their view in the same quarterly print.
Peer performance over the past week provides useful context. BRKR jumped 22% on the week and TXG ran nearly 25%, suggesting the move in ILMN's 12% gain was a rising-tide event rather than stock-specific outperformance. TMO rose a more modest 8%, while IQV and CRL advanced roughly 11-12%. Illumina was not the standout in its peer group — it captured beta without generating alpha, which matters when the question is whether the rally has legs. The ORTEX short score holds at 43, essentially unchanged over the past two weeks, reflecting a market neither strongly bearish nor notably easing on the name.
Next earnings are pencilled in for July 30. Between now and then, the tension between rebuilding short interest, Meister's continued selling programme, and options traders' call-heavy positioning is the data to watch.
See the live data behind this article on ORTEX.
Open ILMN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
